Heraeus Medical Components, a global business unit of Heraeus Holding GmbH, has entered into a purchase agreement for the business acquisition of Biotectix LLC. The acquisition will enable Heraeus Medical Components to offer the Biotectix conductive polymer materials to enhance the performance of sensing and stimulation electrodes used in diagnostic and therapeutic medical devices.
Formed in 2007, Biotectix specializes in polymer based conductive materials for medical devices and is best known for its development of Amplicoat™ and Tecticoat™, two highly durable electro-conductive polymer coatings. Amplicoat™ enhances electrical communication at the interface of human tissue and medical device electrodes while Tecticoat™ provides electrical conductivity, shielding and electrostatic dissipation for skin-contacting applications.
Special conductive polymer coatings like Amplicoat™ bring numerous benefits such as the miniaturization of electrodes while providing the abilities for signal sensing, increased charge delivery and extended battery life for next generation medical devices. But whether it is Tecticoat™, designed for products used outside the body or Amplicoat™ designed for products used inside the body, either coating material can be easily applied to a variety of electrodes for applications including cardiac electrophysiology mapping, pacing, neural recording, neuromodulation and external wearable products.
Commenting on the acquisition, Dr. Nicolas Guggenheim, President of Heraeus Medical Components, said, “We constantly work with our medical device customers to find ways to make products less invasive with added functionality for improved performance and at a lower cost. The medical electrode is a critical part of the equation and Heraeus is a world leader in stimulation electrodes. Biotectix has truly been an innovator with their electro-conductive polymer solutions. Combining our electrode expertise with Biotectix opens up new possibilities for us to deliver new solutions for our customers.”